Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: Retrospective analysis of survival after long-term follow-up

Leukemia Research

Volumn 39, Issue 5, 2015, Pages 520-524

  Cabrero, Monica ^a   Jabbour, Elias ^a   Ravandi, Farhad ^a   Bohannan, Zach ^a   Pierce, Sherry ^a   Kantarjian, Hagop M ^a   Garcia Manero, Guillermo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Hypomethylating agents; Myelodysplastic syndromes; Treatment discontinuation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; HYPOMETHYLATING AGENT; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; DECITABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CANCER SURVIVAL; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHROMOSOME 7; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; CYTOPENIA; DRUG RESPONSE; FEMALE; HEART FAILURE; HIGH RISK PATIENT; HUMAN; KARYOTYPE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT DURATION; TREATMENT WITHDRAWAL; VERY ELDERLY; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DNA METHYLATION; DRUG EFFECTS; FOLLOW UP; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; MYELODYSPLASTIC SYNDROMES; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DNA METHYLATION; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84928052699     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.03.006     Document Type: Article

References (17)

1. Kantarjian H., Issa J.P., Rosenfeld C.S., Bennett J.M., Albitar M., DiPersio J., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106:1794-1803.
2. Issa J.P., Garcia-Manero G., Giles F.J., Mannari R., Thomas D., Faderl S., et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004, 103:1635-1640.
3. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
4. Kantarjian H.M., Thomas X.G., Dmoszynska A., Wierzbowska A., Mazur G., Mayer J., et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012, 30:2670-2677.
5. Garcia-Manero G., Fenaux P. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol 2011, 29:516-523.
6. Garcia-Manero G. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014, 89:97-108.
7. Mayer R.J., Davis R.B., Schiffer C.A., Berg D.T., Powell B.L., Schulman P., et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and leukemia group B. N Engl J Med 1994, 331:896-903.
8. Sekeres M.A., Cutler C. How we treat higher-risk myelodysplastic syndromes. Blood 2014, 123:829-836.
9. Jabbour E., Garcia-Manero G., Batty N., Shan J., O'Brien S., Cortes J., et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 2010, 116:3830-3834.
10. Garcia-Manero G., Kantarjian H.M., Sanchez-Gonzalez B., Yang H., Rosner G., Verstovsek S., et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 2006, 108:3271-3279.
11. Soriano A.O., Yang H., Faderl S., Estrov Z., Giles F., Ravandi F., et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007, 110:2302-2308.
12. Kantarjian H., Oki Y., Garcia-Manero G., Huang X., O'Brien S., Cortes J., et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007, 109:52-57.
13. Cheson B.D., Greenberg P.L., Bennett J.M., Lowenberg B., Wijermans P.W., Nimer S.D., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.
14. Coral S., Parisi G., Nicolay H.J., Colizzi F., Danielli R., Fratta E., et al. Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide. Cancer Immunol Immunother: CII 2013, 62:605-614.
15. Ruter B., Wijermans P.W., Lubbert M. Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2'-deoxycytidine retreatment in high-risk myelodysplasia patients. Cancer 2006, 106:1744-1750.
16. Stresemann C., Bokelmann I., Mahlknecht U., Lyko F. Azacytidine causes complex DNA methylation responses in myeloid leukemia. Mol Cancer Ther 2008, 7:2998-3005.
17. Voso M.T., Breccia M., Lunghi M., Poloni A., Niscola P., Finelli C., et al. Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Eur J Haematol 2013, 90:345-348.